Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

 Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Shots:

  • Purdue to receive one-time payment from Eisai, while releasing itself from rights to develop & commercialize lemborexant. Eisai acquires WW development and commercialization rights for lemborexant, previously held by Purdue in the deal of Aug’15
  • The termination enables Purdue to focus on oncology, non-opioid pain & CNS programs. In Aug’15, Eisai granted WW development & commercialization rights of lemborexant to Purdue and shared clinical study & development costs
  • Lemborexant is a dual orexin receptor antagonist used for insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer’s disease. The US FDA accepted its NDA application with PDUFA date on Dec 27, 2019

Click here to read full press release/ article | Ref: Purdue Pharma | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post